Ischemic Stroke — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for ischemic stroke. 11 active patents protecting 1 drugs from 1+ originators. First major cliff: 2039. Daily refresh.

1
Approved drugs
11
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Ischemic Stroke

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Kk Bcj-94 11 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating ischemic stroke. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Radicava
EDARAVONE
 Kk Bcj-94 11 64 — 2039-11-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12478611 Radicava method of use 75 2041-11-12
12569469 Radicava method of use 75 2041-11-12
12527769 Radicava method of use 75 2041-11-12
12194025 Radicava method of use 75 2041-11-12
12310946 Radicava method of use 75 2041-11-12
11478450 Radicava method of use 70 2039-11-01
12285409 Radicava formulation 55 2039-11-01
11957660 Radicava formulation 55 2039-11-01
11241416 Radicava formulation 50 2039-11-01
11826352 Radicava formulation 50 2039-11-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10987341 Radicava formulation 50 2039-11-01
11241416 Radicava formulation 50 2039-11-01
11826352 Radicava formulation 50 2039-11-01
12285409 Radicava formulation 55 2039-11-01
11957660 Radicava formulation 55 2039-11-01
11478450 Radicava method of use 70 2039-11-01
12478611 Radicava method of use 75 2041-11-12
12569469 Radicava method of use 75 2041-11-12
12527769 Radicava method of use 75 2041-11-12
12194025 Radicava method of use 75 2041-11-12

Related